HCPCS Level II code P3001 represents a screening Papanicolaou (Pap) smear of the cervix or vagina, up to three smears, with interpretation by a physician. As a widely used preventive service in women's health, this code supports cervical cancer screening programs and informs quality measurement and coverage decisions at the national level. Its use affects preventive care access, lab utilization, and clinical workflow for outpatient and ambulatory gynecologic services.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for cervical/vaginal cytology, typical sites of service, and payer coverage patterns. The publication summarizes benchmarks for utilization and reimbursement where available, notes relevant policy and coverage trends affecting screening services, and outlines coding considerations tied to service delivery in outpatient settings.

This summary is intended for health policy analysts, revenue cycle managers, and clinical leaders seeking a national-level briefing on HCPCS Level II code P3001, its role in preventive care, and the payer landscape that shapes access and billing for Pap smear screening.